Comparison, Diabetes

Tresiba vs Levemir: Levemir Is Discontinued, How to Switch to Tresiba

Photo of author

By Health Linear Editorial Team

Updated

A twenty four hour clock face representing Levemir beside a longer forty two hour arc representing Tresiba, each with an insulin pen

Levemir (insulin detemir) has been discontinued in the United States. Novo Nordisk stopped selling Levemir pens and vials on December 31, 2024, and most people who used it have moved to another long-acting insulin, most often Tresiba (insulin degludec) or insulin glargine.

  • Tresiba lasts longer: its effect lasts more than 42 hours, so it is taken once a day at any time, as long as doses are at least 8 hours apart. Levemir lasted up to about 24 hours and often needed two doses a day.
  • Switching from Levemir to Tresiba (US label): adults usually start Tresiba at the same total daily units as their Levemir dose, given once a day. Children aged 1 and older start at 80% of the previous total.
  • Lows: in the DEVOTE trial, severe hypoglycemia was less common with Tresiba than with insulin glargine U-100 (4.9% vs 6.6% of patients).
  • Doses go up slowly: because Tresiba takes 3 to 4 days to reach a steady level, doses should not be changed more often than every 3 to 4 days.
  • Other options: insulin glargine U-100 (Lantus, Basaglar, Semglee, Rezvoglar) or U-300 (Toujeo), and NPH insulin for people who need a lower-cost option.

This is general information, not medical advice. Never switch insulins or change doses without guidance from your diabetes team. Check your blood sugar more often for the first few weeks after any switch.

Tresiba vs Levemir at a glance

Tresiba (insulin degludec)Levemir (insulin detemir)
Status in the USAvailableDiscontinued December 31, 2024
TypeUltra-long-acting basal insulinLong-acting basal insulin
Duration of actionMore than 42 hoursUp to about 24 hours, dose-dependent
Usual dosingOnce daily, any time of day (adults)Once or twice daily
StrengthsU-100 (pen and vial) and U-200 (pen)U-100 only
Maximum per pen injection80 units (U-100 pen); 160 units (U-200 pen)80 units (FlexPen)
Approved agesAdults and children 1 year and olderAdults and children 2 years and older
Use in pregnancyData growing; used when benefits outweigh risksHad the strongest pregnancy data of the newer analogs

Why was Levemir discontinued?

Novo Nordisk said the decision reflected manufacturing capacity, the availability of alternative treatments and changes in insurance coverage. Levemir was an older analog insulin that had lost ground to longer-acting products such as Tresiba and insulin glargine. The company announced the US discontinuation in late 2023, and the FlexPen and vial both ended on December 31, 2024. Other countries followed: the UK, for example, issued guidance in 2025 on moving people off Levemir as supplies ran out.

If you still have Levemir at home, do not use any past its expiry date or that has been open longer than the 42 days the label allowed. Talk to your doctor about a replacement before your supply runs out.

How Tresiba and Levemir differ

Both are “basal” insulins: they provide the steady background insulin your body needs between meals and overnight. They achieve their long action in different ways.

  • Levemir has a fatty acid chain that lets it bind to albumin, a protein in the blood. It is released slowly from the injection site and from albumin, giving up to about 24 hours of effect. At lower doses it often wore off sooner, which is why many people, especially those with type 1 diabetes, took it twice a day.
  • Tresiba forms long chains (multi-hexamers) under the skin after injection. Single insulin molecules break off slowly and steadily, giving a very flat effect that lasts more than 42 hours. Its half-life is about 25 hours.

The very flat, long profile of Tresiba is the main reason for its two practical advantages: fewer night-time lows in some studies, and flexible timing.

Switching from Levemir to Tresiba

The US Tresiba label gives these rules for people switching from another long-acting or intermediate-acting insulin:

  • Adults with type 1 or type 2 diabetes: start Tresiba at the same unit dose as the total daily long-acting or intermediate-acting insulin dose. If you took Levemir twice a day, add the two doses together and take that total once a day as Tresiba.
  • Children aged 1 and older: start Tresiba at 80% of the total daily long-acting or intermediate-acting insulin dose to reduce the risk of low blood sugar.

Many diabetes teams also reduce the starting dose by 10% to 20% in adults who have frequent lows, low body weight or good overall control, then adjust upward. Diabetes UK, for example, says people moving off Levemir will often have their new dose reduced by 10% to 20% at first.

Worked example

BeforeAfter
Levemir 14 units morning and 12 units evening (26 units a day)Adult: Tresiba 26 units once a day, possibly 21 to 23 units if your team reduces it by 10 to 20%
Child on Levemir 10 units a dayTresiba 8 units once a day (80%)

After you switch

  • Check your blood sugar more often, especially fasting and overnight readings, for the first 1 to 2 weeks.
  • Wait 3 to 4 days between dose changes. Tresiba takes about 3 to 4 days to reach a steady level, so changing it every day can stack doses and cause lows.
  • Adjust using fasting glucose. A common approach is to adjust by 2 units every 3 to 4 days until your fasting readings are in your target range.
  • Do not dose-convert the pen. Tresiba FlexTouch pens (both U-100 and U-200) show the actual number of units in the dose window. Dial the number of units your doctor prescribes; no maths is needed.
  • Never draw Tresiba out of a pen with a syringe, especially U-200, as this can cause a serious overdose.

Effectiveness and low blood sugar

Most head-to-head trials found similar HbA1c lowering with Tresiba and other basal insulins when doses are adjusted properly. The differences show up mainly in low blood sugar and convenience.

  • DEVOTE (2017): 7,637 adults with type 2 diabetes at high cardiovascular risk were randomized to Tresiba or insulin glargine U-100. Heart outcomes were similar, but severe hypoglycemia was less common with Tresiba: 4.9% vs 6.6% of patients, a 40% lower rate of severe episodes.
  • SWITCH 1 and SWITCH 2 (2017): in type 1 and type 2 diabetes respectively, Tresiba led to fewer symptomatic and night-time lows than glargine U-100.
  • Children: in a 26-week trial in children aged 1 to 17 with type 1 diabetes, Tresiba controlled blood sugar about as well as Levemir.

Levemir’s main advantages were twice-daily dosing that could be tailored to different day and night needs, and long experience in pregnancy. Those advantages matter less now that it is no longer available.

Other replacements for Levemir

InsulinBrand examplesDurationNotes
Insulin glargine U-100Lantus, Basaglar, Semglee, RezvoglarAbout 24 hoursLower-cost biosimilars available; usually once daily
Insulin glargine U-300ToujeoUp to 36 hoursFlatter than U-100; often needs a slightly higher dose
Insulin degludecTresiba (U-100 and U-200)More than 42 hoursFlexible timing; lowest rate of severe lows in trials
NPH insulinHumulin N, Novolin N12 to 18 hoursCheapest option, sold without a prescription in the US; peaks and needs twice-daily dosing

Your choice depends on insurance coverage, your pattern of highs and lows, whether you are pregnant or planning pregnancy, and how many injections a day you prefer.

Tresiba vs Humalog and NovoLog

People often search “Tresiba vs Humalog” or “Levemir vs Humalog”, but these insulins do different jobs. Humalog (insulin lispro) and NovoLog (insulin aspart) are rapid-acting mealtime insulins. They start working in about 15 minutes, peak in 1 to 2 hours and cover the rise in sugar after you eat. Tresiba and Levemir are background insulins. Many people with type 1 diabetes, and some with type 2, use one of each: a basal insulin once a day plus a mealtime insulin with each meal.

Never confuse the pens. Accidentally injecting a full basal dose of a rapid-acting insulin can cause severe hypoglycemia. Store them apart and check the label every time.

Side effects of Tresiba

  • Low blood sugar (hypoglycemia): the main risk with any insulin. Signs include shaking, sweating, fast heartbeat, hunger, confusion and irritability.
  • Weight gain: common with all insulins.
  • Injection-site reactions and changes in the fat under the skin (lipodystrophy and localized amyloidosis). Rotate injection sites to prevent lumps, which can make insulin absorption unpredictable.
  • Low potassium (hypokalemia).
  • Fluid retention and heart failure if insulin is combined with pioglitazone or rosiglitazone.
  • Allergic reactions: rare, but severe allergic reactions can occur.

Practical tips

  • Pick a routine time. Tresiba allows flexibility, but a fixed daily time makes missed doses less likely. If you miss a dose, take it when you remember, as long as it’s at least 8 hours before the next one.
  • Keep fast-acting sugar with you and make sure someone at home knows how to use glucagon.
  • Ask about cost help. Novo Nordisk’s NovoCare program and insulin price caps under many US plans can lower out-of-pocket costs; biosimilar glargine may be cheaper.
  • Use a continuous glucose monitor if you can. It makes the first weeks after a switch much safer.
  • Store unopened pens in the fridge. Opened Tresiba pens can be kept at room temperature for up to 56 days.

Frequently asked questions

Is Levemir still available in the US?

No. Novo Nordisk discontinued Levemir FlexPen and vials in the US on December 31, 2024. People who used it have been moved to other long-acting insulins such as Tresiba or insulin glargine.

How do I switch from Levemir to Tresiba?

Under the US label, adults usually start Tresiba once daily at the same total daily units as their Levemir dose (both doses added together if taken twice a day). Children aged 1 and older start at 80% of the previous total. Your diabetes team may reduce the dose slightly at first and will adjust it every 3 to 4 days.

Is Tresiba better than Levemir?

Tresiba lasts longer, is usually taken once daily at a flexible time and in trials caused fewer severe and night-time lows than glargine. Blood sugar control is similar. Since Levemir is discontinued in the US, the practical question is which replacement suits you.

What is the difference between Tresiba and Humalog?

Tresiba is a basal (background) insulin that lasts more than 42 hours. Humalog is a rapid-acting mealtime insulin that covers the sugar rise after eating. They do different jobs and are often used together.

Can you take Tresiba twice a day?

Tresiba is designed for once-daily dosing. Splitting it is generally unnecessary because its effect lasts more than 42 hours. Follow your prescriber’s instructions.

How long does it take for Tresiba to work after switching?

It starts working within a few hours of the first dose, but it takes about 3 to 4 days to reach a steady level. That is why doses are adjusted no more often than every 3 to 4 days.

Can I take Tresiba at a different time each day?

Adults can take it at any time of day, but at least 8 hours should pass between doses. Children should take it at the same time each day.

References

About this article

Written by the Health Linear Editorial Team from primary sources such as FDA prescribing information, DailyMed, NIH and peer-reviewed studies, which are linked in the article. Last updated October 30, 2026.

Read our editorial process and medical disclaimer. Spotted an error? Tell us and we will correct it.

Leave a Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.